Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-28T19:07:10.798Z Has data issue: false hasContentIssue false
  • English
  • Français

[No Title]

Published online by Cambridge University Press:  02 January 2018

Paolo Liberini ,
Pierfranco Spano  and
A. Claudio Cuello
Paolo Liberini*
Affiliation:
Division of Pharmacology and Experimental Therapeutics, Brescia University School of Medicine, 25124 Brescia, Italy
Pierfranco Spano
Affiliation:
Division of Pharmacology and Experimental Therapeutics, Brescia University School of Medicine, 25124 Brescia, Italy
A. Claudio Cuello
Affiliation:
Department of Pharmacology and Therapeutics, McGill University, Montreal, PQ, Canada H3G 1Y6
*
∗Department of Biomedical Sciences and Biotechnologies, Division of Pharmacology and Experimental Therapeutics, Brescia University School of Medicine, Via Valsabbina, 19, 25124 Brescia, Italy
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Information
The British Journal of Psychiatry , Volume 163 , Issue 5 , November 1993 , pp. 693 - 694
Copyright
Copyright © Royal College of Psychiatrists, 1993 

References

Davis, K. L., Thal, L. J., Gamzu, E. R., et al (1992) A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. New England Journal of Medicine, 327, 1253–1259.Google Scholar
Farlow, M., Gracon, S. I., Hershey, L. A., et al (1992) A controlled trial of tacrine in Alzheimer's disease. JAMA, 268, 2523–2529.CrossRefGoogle ScholarPubMed
Hefti, F. & Weiner, W. J. (1986) Nerve growth factor and Alzheimer's disease. Annals of Neurology, 20, 275–281.Google Scholar
Liberini, P., Pioro, E., Maysinger, D., et al (1993) Long-term protective effect of human recombinant nerve growth factor and monosialoganglioside GM 1 treatment on primate nucleus basalis cholinergic neurons after neocortical infarction. Neuroscience, 53, 625–637.Google Scholar
Mufson, E. J., Bothwell, M., Hersh, L. B., et al (1989a) Nerve growth factor receptor immunoreactive profiles in the normal, aged human basal forebrain: colocalization with cholinergic neurons. Journal of Comparative Neurology, 285, 196–217.Google Scholar
Mufson, E. J., Bothwell, M. & Kordower, J. H. (1986) Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subrogions of the basal forebrain. Experimental Neurology, 105, 221–232.CrossRefGoogle Scholar
Pearson, R. C. A., Sofroniew, M. V., Cuello, A. C., et al (1983) Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase. Brain Research, 289, 375–379.Google Scholar
Vogels, O. J. M., Broere, C. A. J., Ter Laak, H. J., et al (1990) Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease. Neurobiology of Aging, 11, 3–13.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.